<DOC>
	<DOCNO>NCT02269943</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy CC-486 previously treat subject locally advance metastatic nasopharyngeal carcinoma fail one two previous regimen , include platinum-based chemotherapy . Approximately 51-55 subject enrol accord Simon two-stage design ; predefined activity met ( &gt; 4 response [ complete response ; partial response { CR/PR } ] first 17 evaluable subject base independent radiological assessment ) , study continue enroll additional 34 subject . If &lt; = 4 response 17 observe , study enrollment stop .</brief_summary>
	<brief_title>Safety Efficacy Oral Azacitidine Previously Treated Subjects With Locally Advanced Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age = &gt; 18 year Histological cytological diagnosis undifferentiated poorly differentiate nasopharyngeal carcinoma locally advance metastatic . Disease progression either clinically radiographically 12 previous regimen . Patient receive platinum contain regimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Radiographicallydocumented measureable disease . Adequate organ bone marrow function . Willingness follow pregnancy precaution . History , current brain metastasis . Any malignancy within 5 year prior randomization exception adequately treat situ carcinoma cervix , uteri , nonmelanomatous skin cancer ( treatment complete 6 month prior enrollment ) , situ squamous cell carcinoma breast , incidental prostate cancer . Previous treatment azacitidine ( formulation ) , decitabine , hypomethylating agent . History Gastrointestinal disorder defect . Impaired ability swallow oral medication . Persistent diarrhea malabsorption . Active cardiac disease HIV infection Active Bleeding ; Pathological condition carry high risk bleeding ; risk pseudoaneurysm internal carotid artery carotid blowout syndrome . Major surgery within 14 day prior start Investigational Product recover major side effect . Another investigational therapy within 28 day 5 half life randomization/enrollment , whichever short . Patient recover acute toxic effect prior anticancer therapy , radiation , major surgery/significant trauma . Radiotherapy &lt; = 4 week limited field radiation palliation &lt; = 2 week prior start investigational product . Pregnancy/Breast feed Any condition place patient unacceptable risk he/she participate study confounds ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Metastatic nasopharyngeal carcinoma</keyword>
	<keyword>oral azacitidine</keyword>
	<keyword>oral AZA</keyword>
	<keyword>CC-486</keyword>
	<keyword>metastatic</keyword>
	<keyword>recurrent</keyword>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>nasal</keyword>
	<keyword>solid tumor</keyword>
	<keyword>locally advanced</keyword>
	<keyword>rare head neck cancer</keyword>
	<keyword>nasopharynx</keyword>
	<keyword>single chemotherapy agent</keyword>
	<keyword>Epstein-Barr Virus ( EBV ) + nasopharyngeal carcinoma</keyword>
	<keyword>EBV-DN</keyword>
	<keyword>Celgene</keyword>
	<keyword>Sponsor-study</keyword>
	<keyword>oral chemotherapy</keyword>
	<keyword>phase 2</keyword>
	<keyword>oral Vidaza</keyword>
	<keyword>EBV promoter methylation</keyword>
	<keyword>hypomethylation</keyword>
	<keyword>tumor infiltrate lymphocyte ( TILs )</keyword>
	<keyword>EBV gene expression</keyword>
	<keyword>neoplasm</keyword>
</DOC>